Evaluation of atomoxetine for first-line treatment

Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder
Current Medical Research and Opinion, 09/30/09

Montoya A et al. – A continued improvement of symptoms is expectable until 12 weeks in treatment–naïve ADHD patients treated with atomoxetine as first–line medication. Chief limitations are the small, national sample size and the absence of data beyond the 12–week time–point.